Bibliografía del artículo
1. Lloyd-Jones D, et al. Heart disease and stroke statistics--2010 Update. A report from the American Heart Association. Circulation 2009.
2. Lavados PM, et al. Stroke epidemiology, prevention, and management strategies at a regional level: Latin America and the Caribbean. Lancet Neurol 6(4):362-72, 2007.
3. Petty GW, et al. Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence. Stroke 31(5):1062-8, 2000.
4. Chugh SS, et al. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol, 2001. 37(2): p. 371-8, .
5. Benjamin EJ, et al. Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation 92(4):835-41, 1995.
6. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154(13):1449-57, 1994.
7. Connolly SJ, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139-51, 2009.
8. Hasselblad V. Bridge trial. National Heart, Lung and Blood Institute, 2008.
9. Douketis JD. Perioperative management of warfarin therapy: to bridge or not to bridge, that is the question. Mayo Clin Proc 83(6):628-9, 2008.
10. Douketis JD, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl):299S-339S, 2008.
11. Kovacs MJ, et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation 110(12):1658-63, 2004.
12. Jaffer AK, et al. Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol. J Thromb Thrombolysis 20(1):11-6, 2005.
13. Douketis JD, Johnson JA, Turpie AG, Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med 164(12):1319-26, 2004.
14. Wysokinski WE, et al. Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation. Mayo Clin Proc 83(6):639-45, 2008.
15. Spyropoulos AC, et al. Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy. Chest 125(5):1642-50, 2004.
16. Pengo V, et al. Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study. Circulation 119(22):2920-7, 2009.
17. Spyropoulos AC, et al. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. J Thromb Haemost 4(6):1246-52, 2006.
18. Vink R, et al. Risk of thromboembolism and bleeding after general surgery in patients with atrial fibrillation. Am J Cardiol 96(6):822-4, 2005.
19. Bui HT, et al. Comparison of safety of subcutaneous enoxaparin as outpatient anticoagulation bridging therapy in patients with a mechanical heart valve versus patients with nonvalvular atrial fibrillation. Am J Cardiol 104(10):1429-33, 2009.
20. Baker RI, et al. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 181(9):492-7, 2004.
21. Schulman S, Kearon C, Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692-4, 2005.
22. Rivas-Gandara N, et al. Enoxaparin as bridging anticoagulant treatment in cardiac surgery. Heart 94(2):205-10, 2008.
23. Tafur A, et al. Three month cumulative incidence of thromboembolism and bleeding after periprocedural anticoagulation management of patients with active cancer. Blood 114(22):491, 2009.
24. Gage BF, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 110(16):2287-92, 2004.
25. Dunn AS, Spyropoulos AC, Turpie AG. Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). J Thromb Haemost 5(11):2211-8, 2007.
26. O'Donnell MJ, et al. Preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. Ann Intern Med 146(3):184-7, 2007.
27. Douketis JD, et al. Bridging anticoagulation with low-molecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery. Thromb Haemost 94(3):528-31, 2005.
28. Garcia DA, Spyropoulos AC. Update in the treatment of venous thromboembolism. Semin Respir Crit Care Med 29(1):40-6, 2008.
29. Cheng M, et al. Perioperative anticoagulation for patients with mechanic heart valve(s) undertaking pacemaker implantation. Europace 11(9):1183-7, 2009.
30. Kubitza D, et al. Rivaroxaban (BAY 59-7939)--an oral, direct factor Xa inhibitor--has no clinically relevant interaction with naproxen. Br J Clin Pharmacol 63(4):469-76, 2007.
31. Kubitza D, et al. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin. J Clin Pharmacol 46(9):981-90, 2006.
32. Gulseth MP, Michaud J, Nutescu EA. Rivaroxaban: an oral direct inhibitor of factor Xa. Am J Health Syst Pharm 65(16):1520-9, 2008.
33. Wysokinski W, et al. Predicting left atrial thrombi in atrial fibrillation. Am Heart J (in press).